Use of the piggyBac Transposon to Create Stable Packaging Cell Lines for the Production of Clinical-Grade Self-Inactivating gamma-Retroviral Vectors

摘要

Efforts to improve the biosafety of gamma-retroviral-mediated gene therapy have resulted in a shift toward the use of self-inactivating (SIN) gamma-retroviral vectors. However, scale-up and manufacturing of such vectors requires significant optimization of transient transfection-based processes or development of novel platforms for the generation of stable producer cell clones. To that end, we describe the use of the piggybac transposon to generate stable producer cell clones for the production of SIN y-retroviral vectors. The piggybac transposon is a universal tool allowing for the stable integration of SIN y-retroviral constructs into murine (PG13) and human 293-based Phoenix (GALV and RD114, respectively) packaging cell lines without reverse transcription. Following transposition, a high-titer clone is selected for manufacture of a master cell bank and subsequent gamma-retroviral vector supernatant production. Packaging cell clones created using the piggybac transposon have comparable titers to non-SIN vectors generated via conventional methods. We describe herein the use of the piggybac transposon for the production of stable packaging cell clones for the manufacture of clinical-grade SIN gamma-retroviral vectors for ex vivo gene therapy clinical trials.